How badly does Sanofi chief Paul Hudson want Principia? Enough to ink a $3.7B buyout deal, doubling down on MS
Sanofi CEO Paul Hudson has a home for a chunk of that Regeneron money sitting in the bank.
The pharma exec is shelling out $100 a share to take out Principia $PRNB — helmed by Martin Babler — and the MS drug that Hudson has been talking up for months as a breakthrough in the field. That’s a $3.7 billion deal.
Principia has a whole portfolio of BTK inhibitors in the pipeline, but it’s ‘168 that is the jewel in the crown for Hudson, a partnered drug which he is now doubling down on to help push the “ongoing R&D transformation” at Sanofi. Beyond MS the brain-penetrating drug has potential in other CNS diseases, offering a potential pipeline in a product.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.